Clinical Trial Update: 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC [Phase 1, Phase 2]

View source ↗

Summary

A combination trial of 177Lu-J591 and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer was conducted in Phase 1/2 and subsequently terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-J591
• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-08-24